clinical trial · NCT07223593
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Eli Lilly and Company·phase3·recruiting·n = 1,205
Peripheral Arterial DiseaseOrforglipronPlacebo
brief summary
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
started
Oct 31, 2025
primary completion
Jun 1, 2028
completion
Jun 1, 2028
last updated
Apr 17, 2026
official title
A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol